LLY · Eli Lilly and Company
$1206.512026-07-21Sector: Healthcare; Industry: Drug Manufacturers - General; Sub-Industry: Pharmaceuticals
Intrinsic Value Range Comparison · Mulya.ai
R&D capitalized (5yr)Very High Uncertainty
Bull
$2435
+101.8% vs market
Base · active
$839
-30.5% vs market
Mulya.ai vs Analyst IV Comparison?
Mulya.ai IV range ($504 · $2435) Analysts Range ($1135 · $1400) Fundamentals · historical + forward · baseitalics = DCF projection
| Period | Revenue | Rev Gr ? | Ops M% ? | Tax Rate ? | NOPAT ? | Reinvest ? | FCFF ? | WACC% ? | PV FCFF ? | ROIC ? | Inv. Cap ? | EPS ? | P/E |
|---|
| 2024.Q1 | $34.1B | — | 36.6% | 18.8% | $10.1B | −$16.1B | −$6.0B | 6.4% | — | 16.8% | $60.4B | $5.85 | — |
| 2024.Q4 | $34.1B | 0.0% | 36.6% | 16.5% | $10.4B | −$16.5B | −$6.1B | 6.4% | — | 24.7% | $24.0B | $5.85 | — |
| 2025.Q1 | $45.0B | 32.0% | 45.0% | 18.3% | $16.5B | −$21.0B | −$4.5B | 6.7% | — | 32.0% | $79.3B | $11.82 | — |
| 2025.Q4 | $45.0B | 0.0% | 45.0% | 19.8% | $16.2B | −$18.9B | −$2.6B | 6.2% | — | 30.2% | $28.3B | $11.82 | — |
| 2026.Q1 | $72.3B | 60.4% | 53.1% | 18.8% | $31.1B | −$18.5B | $12.7B | 6.5% | — | 47.2% | $103.6B | $28.21 | 28.2 |
| italics below = DCF projection · 10yr Rev CAGR: 9.6% |
| 2027.Q1 | $89.3B | +23.6% | 61.4% | 18.9% | $44.5B | −$18.5B | $26.0B | 6.6% | $24.4B | 39.4% | $122.1B | $37.08 | 32.5 |
| 2028.Q1 | $102.4B | +14.6% | 57.1% | 19.0% | $47.3B | −$15.4B | $31.9B | 6.8% | $28.1B | 36.5% | $137.5B | $40.30 | 29.9 |
| 2029.Q1 | $113.8B | +11.2% | 52.8% | 19.1% | $48.5B | −$14.8B | $33.7B | 7.0% | $27.7B | 33.5% | $152.3B | $42.36 | 28.5 |
| 2030.Q1 | $124.3B | +9.2% | 48.4% | 19.3% | $48.6B | −$14.3B | $34.3B | 7.2% | $26.2B | 30.5% | $166.6B | $43.60 | 27.7 |
| 2031.Q1 | $135.1B | +8.8% | 39.7% | 19.4% | $43.3B | −$15.7B | $27.6B | 7.4% | $19.6B | 24.8% | $182.3B | $41.73 | 28.9 |
|
| Term. Yr+ | $187.9B | 4.1% | 39.7% | 20.0% | $59.7B | −$10.8B | $48.9B | 8.6% | $526.5B | 22.6% | — | — | — |
Active scenario IV: $839 (-30.5% vs market)